1-(3,5-dimethoxyphenyl)cyclohexanecarbonitrile | 339094-27-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3,5-dimethoxyphenyl)cyclohexanecarbonitrile
• 英文别名: 1-(3,5-Dimethoxyphenyl)cyclohexane-1-carbonitrile
• CAS: 339094-27-8
• 化学式: C₁₅H₁₉NO₂
• 分子量: 245.321
• InChiKey: DFJHAMOQTOPKJC-UHFFFAOYSA-N

物化性质

• 沸点：
  416.3±45.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  42.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(3,5-dimethoxyphenyl)cyclohexanecarbonitrile 在 palladium on activated charcoal 氢气 、 hexamethyldisilazide 、 三溴化硼 、 二异丁基氢化铝 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 77.5h， 生成 5-(1-hexylcyclohexyl)resorcinol
  参考文献：
  名称：

  C1‘-Cycloalkyl Side Chain Pharmacophore in Tetrahydrocannabinols

  摘要：

  In earlier work we have provided evidence for the presence of a subsite within the CB1 and CB2 cannabinoid receptor binding domains of classical cannabinoids. This putative subsite corresponds to substituents on the C1'-position of the C3-alkyl side chain, a key pharmacophoric feature in this class of compounds. We have now refined this work through the synthesis of additional C1'-cycloalkyl compounds using newly developed approaches. Our findings indicate that the C1'-cyclopropyl and C1'-cyclopentyl groups are optimal pharmacophores for both receptors while the C1'-cyclobutyl group interacts optimally with CB1 but not with CB2. The C1'-cyclohexyl analogs have reduced affinities for both CB1 and CB2. However, these affinities are significantly improved with the introduction of a C2'-C3' cis double bond that modifies the available conformational space within the side chain and allows for a better accommodation of a six-membered ring within the side chain subsite. Our SAR results are highlighted by molecular modeling of key analogs.

  DOI：

  10.1021/jm070121a
• 作为产物：
  描述：

  1,5-二溴戊烷 、 3,5-二甲氧基苯基乙腈 在 双(三甲基硅烷基)氨基钾 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以93%的产率得到1-(3,5-dimethoxyphenyl)cyclohexanecarbonitrile
  参考文献：
  名称：

  C1‘-Cycloalkyl Side Chain Pharmacophore in Tetrahydrocannabinols

  摘要：

  In earlier work we have provided evidence for the presence of a subsite within the CB1 and CB2 cannabinoid receptor binding domains of classical cannabinoids. This putative subsite corresponds to substituents on the C1'-position of the C3-alkyl side chain, a key pharmacophoric feature in this class of compounds. We have now refined this work through the synthesis of additional C1'-cycloalkyl compounds using newly developed approaches. Our findings indicate that the C1'-cyclopropyl and C1'-cyclopentyl groups are optimal pharmacophores for both receptors while the C1'-cyclobutyl group interacts optimally with CB1 but not with CB2. The C1'-cyclohexyl analogs have reduced affinities for both CB1 and CB2. However, these affinities are significantly improved with the introduction of a C2'-C3' cis double bond that modifies the available conformational space within the side chain and allows for a better accommodation of a six-membered ring within the side chain subsite. Our SAR results are highlighted by molecular modeling of key analogs.

  DOI：

  10.1021/jm070121a

文献信息

• A New Ring-Forming Methodology for the Synthesis of Conformationally Constrained Bioactive Molecules
  作者：Demetris P. Papahatjis、Spyros Nikas、Andrew Tsotinis、Margarita Vlachou、Alexandros Makriyannis

  DOI：10.1246/cl.2001.192

  日期：2001.3

  A new, general, one pot method for introducing carbocyclic rings alpha to a nitrile moiety is described. Treatment of readily available arylacetonitriles with potassium bis(trimethylsilyl)amide and subsequent alkylation with α, ω-dibromo or dichloroalkanes in tetrahydrofuran under anhydrous conditions at 0 °C produces cycloalkyl adducts in good yields and short reaction times.

  描述了一种新的通用一锅法，用于在腈基前引入碳环。将 readily available 的芳基乙腈与氨基钾双(trimethylsilyl)处理，随后在无水条件下于0 °C的四氢呋喃中与α,ω-二溴或二氯烷烃进行烷基化，可以在短反应时间内以良好的产率生成环烷基附加物。
• CHEMICAL INHIBITORS OF ID PROTEINS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
  申请人：Universität Heidelberg

  公开号：EP3760614A1

  公开（公告）日：2021-01-06

  The present invention relates to compounds of formula (I) or (II) that inhibit expression of Id1 and/or Id3, as well as uses thereof in the treatment of cancer and other diseases and conditions associated with Id1 and/or Id3 expression.

  本发明涉及抑制 Id1 和/或 Id3 表达的式 (I) 或 (II) 化合物，以及其在治疗癌症和其他与 Id1 和/或 Id3 表达相关的疾病和病症中的用途。
• Structural modifications of the cannabinoid side chain towards C3-aryl and 1′,1′-cycloalkyl-1′-cyano cannabinoids
  作者：Demetris P. Papahatjis、Victoria R. Nahmias、Thanos Andreou、Pusheng Fan、Alexandros Makriyannis

  DOI：10.1016/j.bmcl.2005.12.026

  日期：2006.3

  The compounds reported in this study are Delta(8)-THC analogues in which the C3 five-carbon linear side chain of Delta(8)-THC was replaced with aryl and 1',1'-cycloalkyl substituents. Of the compounds described here analogues 2d (CB1, K-i = 11.7 nM. CB2, K-i = 9.39 nM) and 2f (CB1, K-i = 8.26 nM. CB2, K-i = 3.86 nM) exhibited enhanced binding affinities for CB1 and CB2, exceeding that of Delta(8)-THC. Efficient procedures for the synthesis of these novel cannabinoid analogues are described. (C) 2006 Elsevier Ltd. All rights reserved.
• [EN] CHEMICAL INHIBITORS OF ID PROTEINS FOR THE TREATMENT OF CANCER AND OTHER DISEASES<br/>[FR] INHIBITEURS CHIMIQUES DE PROTÉINES ID POUR LE TRAITEMENT DU CANCER ET D'AUTRES MALADIES
  申请人：UNIV HEIDELBERG

  公开号：WO2021001128A1

  公开（公告）日：2021-01-07

  The present invention relates to compounds that inhibit expression of Id1 and/or Id3, as well as uses thereof in the treatment of cancer and other diseases and conditions associated with Id1 and/or Id3 expression.
• C1‘-Cycloalkyl Side Chain Pharmacophore in Tetrahydrocannabinols
  作者：Demetris P. Papahatjis、Victoria R. Nahmias、Spyros P. Nikas、Thanos Andreou、Shakiru O. Alapafuja、Andrew Tsotinis、Jianxin Guo、Pusheng Fan、Alexandros Makriyannis

  DOI：10.1021/jm070121a

  日期：2007.8.1

  In earlier work we have provided evidence for the presence of a subsite within the CB1 and CB2 cannabinoid receptor binding domains of classical cannabinoids. This putative subsite corresponds to substituents on the C1'-position of the C3-alkyl side chain, a key pharmacophoric feature in this class of compounds. We have now refined this work through the synthesis of additional C1'-cycloalkyl compounds using newly developed approaches. Our findings indicate that the C1'-cyclopropyl and C1'-cyclopentyl groups are optimal pharmacophores for both receptors while the C1'-cyclobutyl group interacts optimally with CB1 but not with CB2. The C1'-cyclohexyl analogs have reduced affinities for both CB1 and CB2. However, these affinities are significantly improved with the introduction of a C2'-C3' cis double bond that modifies the available conformational space within the side chain and allows for a better accommodation of a six-membered ring within the side chain subsite. Our SAR results are highlighted by molecular modeling of key analogs.